

CURRICULUM VITAE

NAME: Marianne Ulcickas Yood

ADDRESS: 53 Fenwick
Newton, MA 02468

E-MAIL: muyood@muyood.com

PHONE: 617 527-2800 (office)
203 623 4334 (mobile)

ACADEMIC TRAINING

DSc	Epidemiology Boston University School of Medicine/School of Public Health	1998
MPH	Epidemiology and Biostatistics Boston University School of Medicine/School of Public Health	1990
BS	Anatomy and Physiology Boston University	1986

POSITIONS HELD

2014-present	Member, Board of Directors, Drug Research Group Lexington, MA
2010-present	Member, Editorial Board Pharmacoepidemiology and Drug Safety
2004-present	Principal Epidemiologist EpiSource, LLC Newton, MA
2009-present	Research Associate Professor of Epidemiology Boston University School of Public Medicine/School of Public Health Boston, MA
2008- 2009	Research Scientist Epidemiology and Public Health Yale University School of Medicine New Haven, CT
2001-2008	Associate Research Scientist Epidemiology and Public Health Yale University School of Medicine New Haven, CT
1998-present	Senior Epidemiologist Josephine Ford Cancer Center, Henry Ford Hospital

Detroit, MI

- 2001-2004 Senior Research Director
Galt Associates
Sterling, VA/Hamden, CT
- 1999-2001 Associate Director, Pharmacoepidemiology
Bristol-Myers Squibb Company
Wallingford, CT
- 1998-1999 Associate Director, Oncology Outcomes Research
Bristol-Myers Squibb Company
Wallingford, CT
- 1996-1998 Epidemiologist III
Josephine Ford Cancer Center, Henry Ford Hospital
Detroit, MI
- 1994-1996 Epidemiologist II
Josephine Ford Cancer Center, Henry Ford Hospital
Detroit, MI
- 1992-1994 Epidemiologist I
Biostatistics and Research Epidemiology, Henry Ford Hospital
Detroit, MI
- 1990-1992 Epidemiologist
Boston Collaborative Drug Surveillance Program, Boston University
Lexington, MA
- 1990-1992 Epidemiologist
Center for Human Genetics, Boston University
Boston, MA
- 1990, 1991 Commissioned Officer Student Extern
US Food and Drug Administration, Office of Orphan Products
Rockville, MD
- 1987-1988 Researcher/Writer
Center for the Study of Drug Development, Tufts University
Boston, MA
- 1985-1987 Research Assistant
Department of Neuropathology, Massachusetts General Hospital
Boston, MA
- 1985-1988 Student Intern
US Army Research Institute of Environmental Medicine
Natick, MA

PROFESSIONAL SOCIETIES

1990- present Member, International Society for Pharmacoepidemiology

- 1993- present Member, Society for Epidemiologic Research
- 1998- present Member, American Association for Cancer Research
- 1998- present Member, American Society of Preventive Oncology
- 2011- present Chair, International Society for Pharmacoepidemiology Development Committee

AWARDS AND HONORS

- 2011 Fellow, International Society for Pharmacoepidemiology
- 1999 Bristol-Myers Squibb Excellence Award
- 1995 Society for Epidemiologic Research Student Workshop on Epidemiologic Methods
- 1995 American Society for Preventive Oncology New Investigators Workshop
- 1990 U.S. Public Health Service Achievement Medal
- 1990 U.S. Public Health Service Citation
- 1986 Boston University Dean’s Citation for Student Leadership

FEDERAL FUNDING INFORMATION

- 2009-2012 Cost-Effectiveness of Hormonal Therapy for Clinically Localized Prostate Cancer
Principal Investigator
NCI
The purpose of this study is to measure the total utilization of health care and estimate direct medical care costs over 10 years in men with clinically localized prostate cancer exposed and unexposed to immediate androgen deprivation therapy (ADT) and to estimate the cost per life-year saved and cost per quality-adjusted life-year (QALY) saved of primary ADT, over a 10 year period.

- 2009-2012 Outcomes of Prostate Cancer Androgen Deprivation Therapy
Co-Investigator
NCI
The goal of this study is to estimate prostate cancer-specific, all-cause, and cardiovascular mortality associated with androgen deprivation therapy (ADT) and the risk of serious adverse musculoskeletal, cardiovascular and diabetes events associated with ADT. Another objective is to determine whether the use of preventive medications can favorably modify any association between ADT and adverse events.

- 2010-2014 Statins and Lymphoid Malignancy Risk in a Large Multi-Site Population-Based Cohort
Principal Investigator
NCI
The overall objective of this study is to examine the association between use of statins and risk for lymphoma and whether any association is modified by the presence of conditions related to increased risk for lymphoma.

- 2009-2011 Building a Pharmacovigilance Population-Based Laboratory – CRN3 Administrative Supplement
Co-Investigator
NCI
The purpose of this study is to create automated data infrastructure needed to study exposure to and adverse effects related to chemotherapy exposure and cardiovascular outcomes.

- 2008-2012 Long-term Survivorship in Older Women with Early Stage Breast Cancer
Co-Investigator
NCI
This study is a continuation of the Breast Cancer Treatment and Effectiveness in Older Women (BOW) study in order to extend the follow-up period to fifteen years and to examine the survivorship of older breast cancer patients. This study investigates the potential benefits, costs, and harms of mammography surveillance and long term treatment and health outcomes in older breast cancer survivors.
- 2007-2012 Cancer Research Network Across Health Care Systems (CRN3)
Co-Investigator
NCI
The CRN is a collaboration between researchers affiliated with 11 health care delivery systems across the United States. The overall goal of the CRN is to increase the effectiveness of preventive, curative and supportive interventions that span the natural history of major cancers among diverse populations and health systems, through a program of collaborative research.
- 1995-1997 Patterns and Characteristics of Repeat Screening Mammography in Women Fifty Years and Older
Co-Principal Investigator
Centers for Disease Control and Prevention
This study was designed to describe repeat screening mammography use in a managed care population using automated administrative data.
- 1995-1997 Nonsteroidal Antiinflammatory Drugs and Colorectal Cancer
Principal Investigator
NCI/R03
This study quantified the association between nonsteroidal antiinflammatory drugs and risk for colorectal cancer using automated data and patient interviews.
- 1997-1999 Comparison of Breast Cancer Treatment Regimens by Demographic and Tumor Characteristics
Principal Investigator
Department of Defense Breast Cancer Research Program/Traineeship
This study was designed to describe and compare breast cancer treatments by demographic characteristics using tumor registry and administrative data.
- 1998-2002 Increasing Effectiveness of Cancer Control Interventions
Co-Investigator
NCI/Program Project
A multi-site study to determine and improve the effectiveness of cancer control interventions that span the natural history of major cancers among diverse populations and health systems.

- 1999-2002 HMO Research Network CERT
Co-Investigator (Site Principal Investigator)
AHRQ
This study will create and maintain infrastructure (from HMOs nationwide) that supports research on and improved use of prescription drugs.
- 2001-2002 Hormone Therapy and Prostate Cancer Survival: Pilot Study
Principal Investigator
NCI (supplement)
This study is designed to determine the feasibility of using computerized data for measuring the effect of hormone treatment on prostate cancer survival in a multi-HMO setting.
- 2001-2003 HMO Research Network CERT Prescribing Safety Program
Co-Investigator
AHRQ
This multi-site study will use administrative data combined from HMOs nationwide to identify areas of importance for safe pharmaceutical prescribing.
- 2001-2003 Cancer Surveillance in HMO Administrative Data
Co-Investigator (Site Principal Investigator)
NCI/R01
The purpose of this multi-site study is to determine whether administrative data are adequate for measuring breast and cervical cancer incidence and to evaluate treatment and outcomes for these patients.
- 2003-2007 The HMO Cancer Research Network (CRN)
NCI/Program Project
Co-Investigator
The CRN is a collaboration between researchers affiliated with 11 health care delivery systems across the United States. The *overall goal* of the CRN is to increase the effectiveness of preventive, curative and supportive interventions that span the natural history of major cancers among diverse populations and health systems, through a program of collaborative research.
- 2000-2005 Colon Cancer Survivors: Medications and Risk of Recurrence
Co-Principal Investigator
NCI/R01
The purpose of this study is to determine whether nonsteroidal anti-inflammatory drugs or hormone replacement therapy decrease the risk for recurrent colorectal cancer.
- 2003-2006 Aging Women and Breast Cancer
Co-Investigator (Site Principal Investigator)
NCI/R01
This study is designed to evaluate the receipt and effectiveness of selected breast cancer treatments and surveillance procedures among women 65 years and older. This study is a collaboration between 6 health systems nationwide.

TEACHING AND LECTURES

TEACHING

- 1998-1999 Invited Faculty, Pharmaceutical Education & Research Institute (PERI), Cancer: Pathophysiology, Current Therapies & Clinical Designs course lecture, "Quality of Life Assessment in Cancer Clinical Trials"
- 1997 & 1998 Mentor for Cancer Epidemiology Summer Interns, University of Michigan (Epid. Course 657)
- 1996 & 1997 Mentor for Medical Student Summer Fellowship Program, Medical Education, Henry Ford Hospital
- 1991-1992 Tutor in Epidemiology and Biostatistics, Boston University School of Medicine and School of Public Health
- 1990-1992 Teaching assistant (Chronic Disease Epidemiology and Introduction to Epidemiology), Boston University School of Public Health

PEER-REVIEWED PUBLICATIONS

Ulcickas Yood M, Bortolini M, Casso D, Beck JG, Oliveria S, Wells KE, Woodcroft KJ and Wang LI. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system. *Pharmacoepidemiology and Drug Safety*. 2015 Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/pds.3757.

Johnson CC, Jankowski M, Rolnick S, **Ulcickas Yood M**, Alford SH. Influence of NSAID Use Among Colorectal Cancer Survivors on Cancer Outcomes. *American Journal of Clinical Oncology*. 2014 Dec 10. [Epub ahead of print]

McGlynn KA, Divine GW, Sahasrabudde VV, Engel LS, VanSlooten A, Wells K, **Ulcickas Yood M**, Alford SH. Statin use and risk of hepatocellular carcinoma in a U.S. population. *Cancer Epidemiology*. 2014 Oct;38(5):523-7. doi: 10.1016/j.canep.2014.06.009. Epub 2014 Aug 10.

Jordan JH, Thwin SS, Lash TL, Buist DS, Field TS, Haque R, Pawloski PA, Petersen HV, Prout MN, Quinn VP, **Ulcickas Yood M**, Silliman RA, Geiger AM. Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study. *Breast Cancer Research and Treatment*. 2014 Jul;146(2):401-9. doi: 10.1007/s10549-014-3021-8. Epub 2014 Jun 18.

Yardley DA, Kaufman PA, Brufsky A, **Ulcickas Yood M**, Rugo H, Mayer M, Quah C, Yoo B, Tripathy D. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. *Breast Cancer Research and Treatment*. 2014 Jun;145(3):725-34. doi: 10.1007/s10549-014-2916-8. Epub 2014 Apr 6.

Tsai H, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, **Ulcickas Yood M**, Smith MR, Potosky AL. Risk of Diabetes among Patients Receiving Primary Androgen Deprivation Therapy for Clinically Localized Prostate Cancer. *The Journal of Urology*. 2014 Dec 15. pii: S0022-5347(14)05079-4. doi: 10.1016/j.juro.2014.12.027. [Epub ahead of print]

Potosky AL, Haque R, Cassidy-Bushrow AE, **Ulcickas Yood M**, Jiang M, Tsai HT, Luta G, Keating NL, Smith MR, Van Den Eeden SK. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. *Journal of Clinical Oncology* 2014; March 17 [Epub ahead of print]

Lash TL, Thwin SS, **Ulcickas Yood M**, Geiger AM, Bosco J, Quinn VP, Field TS, Pawloski PA, Silliman RA. Comprehensive evaluation of the incidence of late effects in 5-year survivors of breast cancer. *Breast Cancer Research and Treatment* 2014; Apr;144(3):643-63. doi: 10.1007/s10549-014-2885-y. Epub 2014 Mar 1.

Amiri L, Cassidy-Bushrow AE, Dakki H, Li J, Wells K, Oliveria SA, **Ulcickas Yood M**, Lanfear T. Patient characteristics and participation in a genetic study: a type 2 diabetes cohort. *Journal of Investigative Medicine* 2014;62(1) 26-32.

Haque R, Prout M, Geiger AM, Kamineni A, Thwin SS, Avila C, Silliman RA, Quinn V, **Ulcickas Yood M**. Comorbidities and cardiovascular disease risk in older breast cancer survivors.. *American Journal of Managed Care* 2014;20(1):86-92.

Allen LA, **Ulcickas Yood M**, Wagner EH, Aiello Bowles EJ, Pardee R, Wellman R, Habel L, Nekhlyudov L, Davis RL, Onitilo AA, Magid DJ; Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer. Pharmacovigilance Research Group. *Medical Care*. 2014 May;52(5):e30-8.

Buist DSM, Bosco JLF, Silliman RA, Gold H, Field T, **Ulcickas Yood M**, Quinn VP, Prout M, Lash TL. Survival benefit associated with long-term surveillance mammography in older women with a history of early stage invasive breast cancer. *Breast Cancer Research and Treatment* 2013;142(1):153-63.

Rugo HS, Brufsky AM, **Ulcickas Yood M**, Tripathy D, Kaufman PA, Mayer M, Yoo B, Abidoye O, Yardley DA. Racial disparities in treatment patterns and clinical outcomes in patients with HER-2 positive metastatic breast cancer. *Breast Cancer Research and Treatment* 2013;141(3):461-70.

Tripathy D, Kaufman PA, Brufsky AM, Mayer M, **Ulcickas Yood M**, Yoo B, Quah C, Yardley D, Rugo HS. First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER. *Oncologist* 2013;18(5):501-10.

Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, **Ulcickas Yood M**, McCarty C, Magid DJ, Wagner EH; Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. *Journal of the National Cancer Institute* 2012;104(17):1293-1305.

Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, **Ulcickas Yood M**, Feng S, Wang LI, Quah CS, Yardley DA. Treatment patterns and clinical outcomes in elderly patients with HER-2 positive metastatic breast cancer from the registHER observational study. *Breast Cancer Research and Treatment* 2012;135(3):875-83.

Allen LA, **Ulcickas Yood M**, Wagner EH, Aiello Bowles EJ, Pardee R, Wellman R, Habel L, Nekhlyudov L, Davis RL, Onitilo AA, Magid DJ; for the Pharmacovigilance Research Group. Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer. *Medical Care* Epub 2012 May 25.

Chubak J, Yu O, Pocobelli G, Lamerato L, Webster J, Prout MN, **Ulcickas Yood M**, Barlow WE, Buist DS. Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. *Journal of the National Cancer Institute* 2012;104(12):931-40. Epub 2012 Apr 30.

Ulcickas Yood M, Wells, KE, Hensley Alford S, Dakki H, Beiderbeck A, Hurria A, Gross CP, Oliveria SA. Cardiovascular outcomes in women with advanced breast cancer exposed to chemotherapy. *Pharmacoepidemiology and Drug Safety* 2012;21(8):818-27.

Delate T, Aiello Bowles EJ, Pardee R, Wellman RD, Habel LA, **Ulcickas Yood M**, Nekhlyudov L, Goddard KA, Davis RL, McCarty CA, Onitilo AA, Spencer Feigelson H, Freml J, Wagner E. Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure. *Cancer, Epidemiology, Biomarkers, and Prevention* 2012;21(4):637-80.

Ulcickas Yood M, Oliveria SA, Cziraky M, Hirji I, Hamdan M, Davis C. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. *Current Medical Research and Opinion* 2012; 28(2):213-19.

Ulcickas Yood M, Delorenze GH, Quesenberry CP, Oliveria SA, Tsai A, Kim E, Cziraky MJ, McQuade R, Newcomer JW, L'Italien G. Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose? *BMC Psychiatry* 2011;11(1):197.

Field TS, Bosco JLF, Prout MN, Gold HT, Cutrona S, Pawloski PA, **Ulcickas Yood M**, Quinn VP, Thwin SS, Silliman RA. Age, comorbidity and breast cancer severity- their impact on receipt of definitive local therapy and rate of recurrence among older women with early stage breast cancer. *Journal of the American College of Surgeons* 2011; 213(6):757-65.

Haque R, **Ulcickas Yood M**, Geiger AM, Kamineni A, Avila CC, Shi J, Silliman RA, Quinn VP. Long term safety of radiotherapy and breast cancer laterality in older survivors. *Cancer Epidemiology, Biomarkers and Prevention* 2011; 20(10):2120-6.

Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, **Ulcickas Yood M**, Yardley DA. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: Incidence, treatment and survival in patients from registHER. *Clinical Cancer Research* 2011; 17(14):4834-43.

Davis RL, Eastman D, McPhillips H, Raebel MA, Andrade SE, Smith D, **Ulcickas Yood M**, Dublin S, Platt R. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. *Pharmacoepidemiology and Drug Safety* 2011; 20(2):138-45.

Ulcickas Yood M, DeLorenze G, Quesenberry CP, Tsai A, Phillips S, Willey VJ, Niemcryk S, Wells K, Skovron M, Cziraky MJ, Carson W, Oliveria SA. Epidemiologic study of aripiprazole use and the incidence of suicide events. *Pharmacoepidemiology and Drug Safety* 2010; 10(11):1124-30.

Mapel D, Schum M, **Ulcickas Yood M**, Brown J, Miller D, Davis K. Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators. *Primary Care Respiratory Journal* 2010 19(2):109-17.

Bosco JFL, Silliman RA, Thwin SS, Geiger AM, Buist DSM, Prout MN, **Ulcickas Yood M**, Haque R, Wei F, Lash TL. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. *Journal of Clinical Epidemiology* 2010;63(1):64-74.

Donato BMK, Burns L, Willey V, Cohenuram M, Oliveria S, **Ulcickas Yood M**. Treatment patterns in advanced breast cancer patients exposed to anthracycline, taxane, and capecitabine: A descriptive report. *Clinical Therapeutics* 2010; 32(3):546-54.

Ulcickas Yood M, Delorenze GH, Quesenberry CP, Oliveria SA, Tsai A, Willey VJ, McQuade R, Newcomer JW, L'Italien G. The incidence of diabetes in atypical antipsychotic users differs according to agent--Results from a multisite epidemiologic study. *Pharmacoepidemiology and Drug Safety* 2009; 18(9):791-9.

Kozloff M, **Ulcickas Yood M**, Flynn PJ, Berlin J, Kabbinavar FF, Sargent D, Purdie DM, Dong W, Sugrue MM, Grothey A. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study. *Oncologist* 2009;14(9):862-70. Epub 2009 Sep 2.

Gold HT, Thwin SS, Buist DSM, Field TS, Wei F, **Ulcickas Yood M**, Quinn V, Lash TL, Geiger AM, Silliman RA. Radiotherapy delay in older women with early stage breast cancer in integrated healthcare delivery systems. *American Journal of Managed Care* 2009;15:785-789.

Ahern TP, Bosco JLF, Silliman RA, **Ulcickas Yood M**, Field TS, Wei F, Lash TL. Potential misinterpretations caused by collapsing upper categories of comorbidity indices: an illustration from a cohort of older breast cancer survivors. *Clinical Epidemiology* 2009;1:93-100.

Lafata JE, Dobie EA, Divine GW, **Ulcickas Yood M**, McCarthy BD. Sustained hyperglycemia among patients with diabetes: what matters when action is needed? *Diabetes Care* 2009;32(8):1447-52.

Buist DSM, Chubak J, Prout M, **Ulcickas Yood M** Bosco JLF, Thwin SS, Gold HT, Owusu C, Field TS, Quinn VP, Wei F, Silliman RA. Referral, receipt and completion of chemotherapy in early stage breast cancer patients aged 65 and older at high-risk of breast cancer recurrence. *Journal of Clinical Oncology* 2009;27:4508-14. Epub 2009 Aug 17.

Ulcickas Yood M, Oliveria SA, Campbell UB, Koro KE. Incidence of cancer in a population-based cohort of patients with Type 2 diabetes. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 2009;3:12-16.

Oliveria SA, Koro CE, **Ulcickas Yood M**, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 2008;2:47-57.

Goff SL, Feld A, Andrade SE, Mahoney L, Beaton SJ, Boudreau DM, Davis RL, Goodman M, Hartsfield CL, Platt R, Roblin D, Smith D, **Ulcickas Yood M**, Dodd K, Gurwitz GH. Administrative data used to identify patients with irritable bowel syndrome. *Journal of Clinical Epidemiology* 2008;61(6):617-21. Epub 2008 Mar 4.

Field TS, Doubeni C, Fox MP, Buist DSM, Wei F, Geiger AM, Quinn VP, Lash TL, Prout MN, **Ulcickas Yood M**, Frost FJ, Silliman RA. Under utilization of surveillance mammography among older breast cancer survivors. *Journal of General Internal Medicine* 2008;23(2):158063. Epub 2007 Dec 1.

Oliveria SA, Menditto LA, **Ulcickas Yood M**, Koo YH, Wells KE, McCarthy BD. Barriers to initiation of and persistence with insulin therapy. *Current Medical Research and Opinion* 2007;23:3105-12.

Stang PE, Frank C, **Ulcickas Yood M**, Wells K, Burch S. Impact of Bipolar Disorder: Results from a screening study. *Journal of Clinical Psychiatry Primary Care Companion* 2007;9:42-47.

Ulcickas Yood M, Owusu C, Buist DSM, Geiger AM, Field TS, Thwin SS, Lash TL, Prout MN, Wei F, Quinn VP, Frost FJ, Silliman RA. Mortality impact of less than standard therapy in older breast cancer patients. *Journal of the American College of Surgeons* 2008;206:66-75. Epub 2007 Oct 3.

Ulcickas Yood, M, Campbell UB, Rothman KJ, Jick SS, Lang J, Wells KE, Jick H, Johnson CC. Using prescription claims data for drugs available over the counter (OTC). *Pharmacoepidemiology and Drug Safety* 2007;16:961-8.

Fortuny J, Johnson C, Bohlke K, Chow W-H, Hart G, Kucera G, Mujumdar U, Ownby D, Wells K, **Ulcickas Yood M**, Engel LS. Use of anti-inflammatory drugs and lower esophageal sphincter relaxing drugs and risk of esophageal and gastric cancers. *Clinical Gastroenterology and Hepatology* 2007;5:1154-1159. Epub 2007 Jul 23.

Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, **Ulcickas Yood M**, Platt R. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. *Pharmacoepidemiology and Drug Safety* 2007;16:1086-94.

Owusu C, Buist DSM, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, **Ulcickas Yood M**, Wei F, Silliman RA. Predictors of tamoxifen discontinuation among older women with estrogen-receptor positive breast cancer. *Journal of Clinical Oncology* 2008;26:549-55. Epub 2007 Dec 10.

Buist DSM, Ichikawa L, Prout MN, **Ulcickas Yood M**, Field T, Owusu C, Geiger AM, Quinn VP, Wei F, Silliman RA. Receipt of primary breast cancer therapy and adjuvant therapy are not associated with obesity in older women treated in integrated health plans. *Journal of Clinical Oncology* 2007;25:3428-3436.

Lash TL, Fox MP, Buist DSM, Wei F, Field TS, Frost FJ, Quinn VP, **Ulcickas Yood M**, Silliman RA. Mammography Surveillance and Mortality in Older Breast Cancer Survivors. *Journal of Clinical Oncology* 2007;25:3001-6. Epub 2007 Jun 4.

Ulcickas Yood M, Quesenberry CP, Guo D, Wells K, Shan J, Sanders L, Skovron M, Iloeje U, Caldwell C, Manos MM. Incidence of hepatocellular carcinoma among individuals with Hepatitis B Virus infection identified using an automated data algorithm. *Journal of Viral Hepatitis* 2008;15:28-36. Epub 2007 Sep 24.

Lash TL, Fox MP, Thwin SS, Geiger A, Buist DSM, Wei F, Field TS, **Ulcickas Yood M**, Frost FJ, Enger SM, Prout MN, Silliman RA. Probabilistic corrections to account for abstractor agreement in medical record reviews. *American Journal of Epidemiology* 2007;165:1454-61. Epub 2007 Apr 3.

Mapel DW, Nelson LS, Lydic E, Soriano J, **Ulcickas Yood M**, Davis K. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. *Journal of Chronic Obstructive Pulmonary Disease* 2007;4:127-134.

Ulcickas Yood M, Quesenberry CP, Guo D, Caldwell C, Wells K, Shan J, Sanders L, Skovron M, Iloeje U, Manos MM. Incidence of non-Hodgkin's lymphoma among individuals with chronic Hepatitis B virus infection. *Hepatology* 2007;46:107-12. Epub 2007 May 24.

Geiger AM, Thwin SS, Lash TL, Buist DSM, Prout M, Wei F, Field TS, **Ulcickas Yood M**, Frost FJ, Enger SM, Silliman RA. Breast cancer recurrence in older women in relation to receipt of standard treatments for the primary tumor. *Cancer* 2007;109:966-74.

Stang P, Morris L, Kempf J, Henderson S, **Ulcickas Yood M**, Oliveria S. The co-prescription of contraindicated drugs with statins: continuing potential for increased risk of adverse events. *American Journal of Therapeutics* 2007;14:30-40.

Elston Lafata J, Simpkins J, Kaatz S, Horn JR, Raebel MA, Schultz L, Smith DH, **Ulcickas Yood M**. What do medical records tell us about potentially harmful co-prescribing? *Joint Commission Journal on Quality and Patient Safety* 2007;33:395-400.

Arellano FM, **Ulcickas Yood M**, Wentworth CE, Oliveria S, Rothman KJ. Use of cyclo-oxygenase-2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAID) in a UK and a USA population: Implications for COX-2 cardiovascular profile. *Pharmacoepidemiology and Drug Safety* 2006;15:861-872.

Ulcickas Yood M, Elston Lafata J, Koro C, Wells KE, Pladevall M. Time to pharmacotherapy change in response to elevated HbA_{1c} Test Results. *Current Medical Research and Opinion* 2006;22:1567-1574.

Enger SM, Thwin SS, Buist DS, Field T, Frost F, Geiger AM, Lash TL, Prout M, **Ulcickas Yood M**, Wei F, Silliman RA. Breast cancer treatment among older women in integrated health care settings. *Journal of Clinical Oncology* 2006;24:4377-4383.

Stang PE, Krishnan A, Frank C, **Ulcickas Yood M**, Wells K. The clinical history and costs associated with delayed diagnosis of bipolar disorder. *Medscape General Medicine* 2006;8(2):18.

Ulcickas Yood M, McCarthy BD, Kempf J, Kucera G, Wells K, Oliveria S, Stang P. Racial differences in reaching target low density lipoprotein goal among individuals treated with prescription statin therapy. *American Heart Journal* 2006;152:777-84.

Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Roblin D, Smith DH, **Ulcickas Yood M**, Platt R, Gurwitz JH. Use of prescription medications with a potential for fetal harm among pregnant women. *Pharmacoepidemiology and Drug Safety* 2006;15:546-54.

Doubeni C, Field T, **Ulcickas Yood M**, Rolnick S, Quesenberry CP, Fouayzi H, Gurwitz J, Wei FX. Patterns and predictors of mammography utilization among breast cancer survivors. *Cancer* 2006;106:2482-8.

Stang PE, Frank C, **Ulcickas Yood M**, Wells K, Burch S, Muma B. Bipolar disorder detection, ascertainment, and treatment: Primary care physician knowledge, attitudes and awareness. *Primary Care Companion to the Journal of Clinical Psychiatry* 2006; 8:147-152.

Ulcickas Yood M, Watkins E, Wells K, Kucera G, Johnson CC, Lydick E. The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. *Pharmacoepidemiology and Drug Safety* 2006;15:852-860.

Elston Lafata J, Schultz L, Simpkins J, Chan KA, Horn JR, Kaatz S, Long C, Platt R, Raebel MA, Smith DH, Xi H, **Ulcickas Yood M**. Potential drug-drug interactions in the outpatient setting. *Medical Care* 2006;44:534-41.

Cooper GS, Johnson CC, Lamerato L, Poisson LM, Schultz L, Simpkins J, Wells K, **Ulcickas Yood M**, Chase G, Nathanson D, Elston Lafata J. Use of guideline recommended follow up care in cancer survivors: routine or symptom driven indications? *Medical Care* 2006; 44:590-4.

Ulcickas Yood M, Quesenberry CP, Alford SH, Tsai A, Wells KE, Yood SM, Ackermann Shiff SP. An observational study examining the impact of capecitabine on warfarin antithrombotic activity and bleeding complications. *Current Medical Research and Opinion* 2006;22:307-314.

Rolnick S, Kucera GP, Hensley Alford S, Fortman K, **Ulcickas Yood M**, Jankowski M, Johnson CC. Racial and age differences in colon examination surveillance following a diagnosis of colorectal cancer. *Journal of the National Cancer Institute Monographs* 2005;35:96-101.

Mouchawar J, Taplin S, Ichikawa L, Barlow WE, Geiger A, Weinmann S, Gilbert J, Manos M, **Ulcickas Yood M**. Late stage breast cancer among women with recent negative screening mammography: missed clinical opportunities? *Journal of the National Cancer Institute Monographs* 2005;35:39-46.

Weinmann S, Taplin S, Gilbert J, Beverly K, Geiger A, **Ulcickas Yood M**, Mouchawar J, Manos MM, Zapka J, Westbrook E, Barlow W. Characteristics of women with breast cancer who refused follow-up for screening tests of suspicious symptoms. *Journal of the National Cancer Institute Monographs* 2005;35:33-38.

Zapka JG, Puleo E, Taplin S, Solber LI, Mouchawar J, Somkin C, Geiger A, **Ulcickas Yood M**. Breast and cervical cancer screening: Clinicians' views on health plan guidelines and implementation efforts. *Journal of the National Cancer Institute Monographs* 2005;35:46-54.

Puleo E, Zapka JG, Valentine Goins K, **Ulcickas Yood M**, Taplin S, Mouchawar J, Manos M, Somkin C. Accurate reporting of recommendations of care related to follow-up of abnormal cancer screening tests. Submitted to *Evaluation and the Health Professions* 2005;28:310-27.

Taplin SH, Barlow WE, **Ulcickas Yood M**, Westbrook E, Geiger AM, Bischoff K, Ichikawa L. Re: Breast cancer comes full circle. Response (letter). *Journal of the National Cancer Institute* 2005;97:461.

Leyden WA, Manos MM, Geiger AM, Weinmann S, Taplin SH, Mouchawar J, Bischoff K, **Ulcickas Yood M**, Gilbert J. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. *Journal of the National Cancer Institute* 2005;97:675-83.

Elston Lafata J, Simpkins J, Shultz L, Chase GA, Johnson CC, **Ulcickas Yood M**, Lamerato L, Nathanson D, Cooper G. Receipt of routine surveillance care following cancer treatment with curative intent. *Medical Care* 2005;43:592-9.

Taplin S, **Ulcickas Yood M**, Geiger A, Ichikawa L, Bischoff K, Barlow W. Re: Reason for late-stage breast cancer: absence of screening or detection or breakdown in follow-up? Response (letter). *Journal of the National Cancer Institute* 2004;97:400-401.

Taplin SH, Ichikawa L, **Ulcickas Yood M**, Manos MM, Geiger A, Weinman S, Gilbert J, Mouchawar J, Leyden W, Altaras R, Beverly K, Casso D, Westbrook E, Zapka J, Barlow WE. Reasons for late-stage breast cancer among women with access to care: absence of screening, absence of detection or potential breakdown in followup? *Journal of the National Cancer Institute* 2004;96:1518-27.

Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH, **Ulcickas Yood M**, Morse AN, Platt R. Prescription drug use in pregnancy. *American Journal of Obstetrics and Gynecology* 2004;191:398-407.

Zapka JG, Puleo E, Taplin S, Valentine Goins K, **Ulcickas Yood M**, Mouchawar J, Somkin C, Manos M. Processes of care in cervical and breast cancer screening and follow-up-- The importance of communication. *Preventive Medicine* 2004;39:81-90.

Oliveria SA, **Ulcickas Yood M**, Cambell UB, Yood SM, Stang P. Treatment and referral patterns for colorectal cancer. *Medical Care* 2004;42:901-906.

Valentine Goins K, Zapka JG, Geiger AM, Solberg LI, Taplin S, **Ulcickas Yood M**, Gilbert J, Mouchawar J, Somkin C, Weinmann S. Implementation of systems strategies for breast and cervical cancer screening services in health maintenance organizations. *American Journal of Managed Care* 2003;9:745-755.

Ulcickas Yood M, Oliveria S, Boyer JG, Wells K, Stang P, Johnson CC. Colon polyp recurrence in a managed care population. *Archives of Internal Medicine* 2003;163:422-426.

Delea TE, Vera-Llonch M, Edelsberg JS, McGarry L, Anton S, **Ulcickas Yood M**, Oster G. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. *Value in Health* 2002;5:35-43.

Platt R, Davis R, Finkelstein J, Go A, Gurwitz J, Roblin D, Soumerai S, Ross-Degnan D, Andrade S, Goodman M, Martinson B, Raebel M, Smith D, **Ulcickas Yood M**, Chan A. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics (CERTs). *Pharmacoepidemiology and Drug Safety* 2001; 10:373-377.

Ulcickas Yood M, Johnson CC, Blount A, Abrams J, Wolman E, McCarthy BD, Raju U, Nathanson DS, Worsham M, Wolman SR. Race and differences in breast cancer survival in a managed care population. *Journal of the National Cancer Institute* 1999;91:1487-1491.

Ulcickas Yood M, McCarthy BD, Lee NC, Jacobsen G., Johnson CC. Patterns and Characteristics of Repeat Mammography Among Women 50 Years and Older. *Cancer Epidemiology, Biomarkers and Prevention* 1999;8:595-599.

Velanovich V, **Ulcickas Yood M**, Bawle U, Nathanson SD, Strand VF, Talpos GB, Szymanski W, Lewis FR. Racial differences in the presentation and surgical management of breast cancer. *Surgery* 1999;125:375-379.

Baker AM, McCarthy BD, Gurley VF, **Ulcickas Yood M**. Influenza immunization in a managed care organization: A randomized, controlled trial and cost-effectiveness analysis comparing computerized mailed reminders. *Journal of General Internal Medicine* 1998;13:469-475.

McCarthy BD, **Ulcickas Yood M**, Bolton M, Boohaker EA, MacWilliam CH, Young MJ. Redesigning the primary care process to improve the offering of mammography. The use of clinic protocols by non-physicians. *Journal of General Internal Medicine* 1997;12:357-363.

MacWilliam CH, **Ulcickas Yood M**, Verner J, McCarthy BD, Ward RE. Patient related risk factors which predict poor outcome after total hip replacement. *Health Services Research* 1996;31:623-38.

McCarthy BD, **Ulcickas Yood M**, Boohaker EA, Ward RE, Rebner M, Johnson CC. Inadequate follow-up of abnormal mammograms. *American Journal of Preventive Medicine* 1996;12:282-8.

McCarthy BD, **Ulcickas Yood M**, Janz NK, Boohaker EA, Ward RE, Johnson CC. Evaluation of factors potentially associated with inadequate follow-up of mammographic abnormalities. *Cancer* 1996;77:2070-6.

McCarthy BD, **Ulcickas M**, Wilcock CH, Lee M. Screening mammography use: the importance of a population perspective. *American Journal of Preventive Medicine* 1996;12:91-5.

Copeland M, Senkowski C, **Ulcickas M**, Mendelsohn M, Griep R. Breast size as a risk factor for sternal wound complications in women undergoing cardiac surgery. *Archives of Surgery* 1994;129:757-759.

Berman I, **Ulcickas M**, Yood SM, Grant RL. Cancer trends unique to Georgia. *Journal of the Medical Association of Georgia*. 1993;82:29-33.

Milunsky A, Morris S, Jick H, Rothman KJ, **Ulcickas M**, Jick SS, Shoukimas P, Willet W. Maternal zinc and fetal neural tube defects. *Teratology* 1992;46:341-348.

Jick H, **Ulcickas M**. Comparison of frequencies of suicidal tendencies among patients receiving fluoxetine, lofepramine, mianserin or trazodon. *Pharmacotherapy* 1992;12:451-454.

Milunsky A, **Ulcickas M**, Rothman KJ, Willett W, Jick SS, Jick H. Maternal heat exposure and neural tube defects. *JAMA* 1992;268(7):882-885.

Shulman S, Dicerbo P, **Ulcickas M**. A survey of therapeutic substitution programs in ten Boston area hospitals. *Drug Information Journal* 1992;26:41-52.

Ulcickas M. The Orphan Drug Act: A discussion of issues surrounding the legislation and its implementation. *Drug News and Perspectives* 1990;3:307-308.

Richard B, **Ulcickas M**. Approvable letters in the FDA new drug approval process. *Journal of Clinical Pharmacology* 1989;29:680-684.

Wastila L, **Ulcickas M**, Lasagna L. The World Health Organization's essential drug list: the significance of "me-too" and follow-on research. *Journal of Clinical Research and Drug Development* 1989;3:105-115.

Shulman S, **Ulcickas M**. Update on ADR reporting regulations: products liability implications. *Journal of Clinical Research and Drug Development* 1989;3:91-103.

BOOK CHAPTERS

Platt R, Andrade SE, Davis RL, Destefano F, Finkelstein JA, Goodman M, Gurwitz JH, Go AS, Martinson BC, Raebel MA, Roblin D, Ross-Degnan D, Soumerai SB, Smith DH, **Ulcickas Yood M**,

Chan KA. Pharmacovigilance in the HMO Research Network In: Mann R and Andrews E, eds. Pharmacovigilance. John Wiley and Sons, 2002.